-
21.发明授权公开(公告)号：US11884727B2
公开(公告)日：2024-01-30
申请号：US17186960
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P25/28 , A61P37/02 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/3955 , A61K39/39541 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K38/208 , A61K2300/00 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
公开(公告)号：US20240026357A1
公开(公告)日：2024-01-25
申请号：US18221914
申请日：2023-07-14
Inventor： Alon CHEN , Sharon MANASHIROV , Andres Pablo MONTEFELTRO
IPC: C12N15/113 , A61K47/55 , A61K47/54 , A61P25/24
CPC classification number: C12N15/113 , A61K47/55 , A61K47/548 , A61P25/24 , C12N2310/141
Abstract: A composition of matter comprising a synthetic miR-135 molecule comprising a nucleic acid sequence of a miR-135b as set forth in SEQ ID NO: 37, and a complementary strand as set forth in SEQ ID NO: 40 is disclosed. A conjugate comprising a composition of matter comprising a synthetic miR-135 molecule and a cell-targeting moiety is also disclosed.
-
公开(公告)号：US20240010973A1
公开(公告)日：2024-01-11
申请号：US18226877
申请日：2023-07-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaqub HANNA , Sergey VIUKOV , Emilie WILDSCHUTZ , Noa NOVERSHTERN , Carine JOUBRAN , Segev NAVEH TASSA , Alejandro CASTREJON AGUILERA , Bernardo OLDAK , Shadi TARAZI , Francesco RONCATO
IPC: C12N5/073
CPC classification number: C12N5/0604 , C12N2506/03 , C12N2501/155 , C12N2501/115 , C12N2501/119 , C12N2501/91 , C12N2500/02
Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.
-
公开(公告)号：US20240009315A1
公开(公告)日：2024-01-11
申请号：US18229224
申请日：2023-08-02
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Gideon SCHREIBER , Jiri ZAHRADNIK , Amnon BAR-SHIR , Yinon RUDICH , Andrea GALISOVA
CPC classification number: A61K47/64 , A61K47/6911
Abstract: Particles having an ACE2 targeting moiety attached to an outer surface thereof are disclosed herein. The ACE2 targeting moiety comprises a polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD), wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501. Uses of the particles for treatment and diagnosis of diseases are also disclosed.
-
公开(公告)号：US20240009287A1
公开(公告)日：2024-01-11
申请号：US18234935
申请日：2023-08-17
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ravid STRAUSSMAN , Oded SANDLER , Reut RIFF
CPC classification number: A61K39/0011 , A61P35/00 , A61K2039/52 , A61K2039/6006 , A61K2039/627
Abstract: A vaccine comprising a pharmaceutically acceptable carrier and bacteria which presents at least one cancer-associated antigen is disclosed. The bacteria are not genetically modified to express the at least one cancer-associated antigen. Uses thereof are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US20230419149A1
公开(公告)日：2023-12-28
申请号：US18299792
申请日：2023-04-13
Inventor： Gil SEMO , Ziv AQUA , Oded MELAMED , Dan CHARASH , Serge ROSENBLUM , Barak DAYAN
Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.
-
公开(公告)号：US20230415378A1
公开(公告)日：2023-12-28
申请号：US18049648
申请日：2022-10-26
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Daniel Hanoch WAGNER , Mark SHNEIDER
IPC: B29B7/00 , B29B7/10 , D04H1/728 , D04H1/4326 , D01D5/00
CPC classification number: B29B7/005 , B29B7/10 , D01D5/003 , D04H1/4326 , D04H1/728
Abstract: The presently disclosed subject matter relates to the field of electrospun epoxy fibers, a solution for producing the fibers and a system for electrospinning the fibers. This invention further relates to processes of producing the solution and the fibers. By dissolving epoxy in a dielectric solvent, suitable electrospinning conditions are achieved by controlling the degree of epoxy crosslinking in the solution. The fibers are captured on a net screen, with the positive electrode placed behind it. The resulting electrospun fibers exhibit superior mechanical properties in comparison with other epoxy fibers. This improvement in mechanical properties is, in part, due to anisotropic molecular rearrangement resulting from the strong stretching forces induced by electrospinning.
-
28.发明授权公开(公告)号：US11852634B2
公开(公告)日：2023-12-26
申请号：US17081013
申请日：2020-10-27
Inventor： Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Meirav Pevsner-Fischer
IPC: G01N33/68 , A61K38/08 , A61K38/18 , A61K31/343 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/543
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/185 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
公开(公告)号：US20230256028A1
公开(公告)日：2023-08-17
申请号：US18137449
申请日：2023-04-21
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair REISNER , Carmit HILLEL-KARNIEL , Chava ROSEN , Esther BACHAR-LUSTIG , Elias SHEZEN
CPC classification number: A61K35/42 , A61P11/00 , A61K9/0019 , A61K35/28
Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.
-
公开(公告)号：US11684578B2
公开(公告)日：2023-06-27
申请号：US16485855
申请日：2018-02-16
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Jacob Klein , Ronit Goldberg , Weifeng Lin
CPC classification number: A61K9/1273 , A61K9/0019 , A61P19/02
Abstract: A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises:
a) at least one bilayer-forming lipid;
b) a polymeric compound having the general formula I:
wherein m, n, L, X, Y, and Z are as defined herein; and
c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.
-
-
-
-
-
-
-
-
-
Search Results
987
records
(took 0.039 seconds)
